SALDISK 50 µg/1 doza+ 100 µg/1 doza prašak inhalata, dozirani Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

saldisk 50 µg/1 doza+ 100 µg/1 doza prašak inhalata, dozirani

salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 100 µg/1 doza - 1 doza praška inhalata, doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 100 µg flutikazonpropionata

SALDISK 50 µg/1 doza+ 250 µg/1 doza prašak inhalata, dozirani Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

saldisk 50 µg/1 doza+ 250 µg/1 doza prašak inhalata, dozirani

salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 250 µg/1 doza - 1 doza praška inhalata doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 250 µg flutikazonpropionata

SALDISK 50 µg/1 doza+ 500 µg/1 doza prašak inhalata, dozirani Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

saldisk 50 µg/1 doza+ 500 µg/1 doza prašak inhalata, dozirani

salvus bh d.o.o. - flutikazon, Салметерол - prašak inhalata, dozirani - 50 µg/1 doza+ 500 µg/1 doza - 1 doza praška inhalata, doziranog sadrži: 50 µg salmeterola (u obliku salmeterolksinafoata) 500 µg flutikazonpropionata

Iclusig Europska Unija - hrvatski - EMA (European Medicines Agency)

iclusig

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. pogledajte odjeljke 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Pemazyre Europska Unija - hrvatski - EMA (European Medicines Agency)

pemazyre

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - antineoplastična sredstva - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Minjuvi Europska Unija - hrvatski - EMA (European Medicines Agency)

minjuvi

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Opzelura Europska Unija - hrvatski - EMA (European Medicines Agency)

opzelura

incyte biosciences distribution b.v. - ruxolitinib phosphate - vitiligo - ostali dermatološki pripravci - opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

Sycrest Europska Unija - hrvatski - EMA (European Medicines Agency)

sycrest

n.v. organon - asenapine (as maleate)  - bipolarni poremećaj - psycholeptics - sycrest je indiciran za liječenje umjerenih do teških maničnih epizoda povezanih s bipolarnim poremećajem u odraslih osoba.

Benlysta Europska Unija - hrvatski - EMA (European Medicines Agency)

benlysta

glaxosmithkline (ireland) limited - belimumab - lupus erythematosus, sistemski - imunosupresivi - benlysta navodi kao dopuna terapije kod pacijenata u dobi od 5 i više godina uz aktivnu, pozitivnu аутоантитела sistemski eritemski lupus (sle) s visokim stupnjem aktivnosti bolesti (e. pozitivna anti-ova dnk i niska razina komplementa), bez obzira na standardnu terapiju. benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.

Cetrotide Europska Unija - hrvatski - EMA (European Medicines Agency)

cetrotide

merck europe b.v. - cetrorelix (as acetate) - ovulation; ovulation induction - hipofiza i hipotalamusni hormoni i analozi - prevencija preuranjene ovulacije kod pacijenata koji su podvrgnuti kontroliranoj stimulaciji jajnika, nakon čega slijedi uzimanje oocita i pomoćno-reproduktivne tehnike. u kliničkim ispitivanjima, cetrotide koristi ljudski менопаузальный gonadotropin (hmg), međutim, ograničeno iskustvo primjenu rekombinantnog folikul stimulirajući (fsh) ponudili istu učinkovitost.